Delivery Order 75N91019D00025-75N91019F00130
Award Date
9/19/19
Potential Completion Date
5/31/24
Potential Value
$4.2M
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
3
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The contract is for "Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases" and has a ceiling value of $1,672,101.05. It is a cost-plus-fixed-fee delivery order contract with a period of performance through July 2022....
This federal contract award, valued at $1,469,410.09, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS). The contract was awarded to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods and a leading contract research and manufacturing organization specializing in the development of gene therapies, vaccines, oncolytics, and immunotherapies. The contract is for NIAID...
This is a definitive contract awarded by the National Cancer Institute (NCI), a part of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The $4,712,200.49 cost-plus-fixed-fee contract supports research on retroviral pathogenesis, treatment, and prevention. It has an ultimate completion date of November 30, 2014 and does not have a set-aside designation. ABL has significant expertise in biologics...
The federal contract award is to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit organization that specializes in the development of gene therapies, vaccines, oncolytics, and immunotherapies. The contract, with a ceiling value of $2,745,187.57, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract is a Delivery Order with a...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $29,859.00 fixed-price delivery order is for the manufacture of master cell banks to support pandemic preparedness and the COVID-19 response. The ultimate completion date is April 15, 2025. ABL is an experienced contractor that has been awarded multiple Indefinite Delivery...
This is a task order awarded under the Preclinical Services for Biopharmaceutical Product Development indefinite-delivery/indefinite-quantity (IDIQ) contract by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases. The $110,115.92 task order was awarded to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit organization that specializes in manufacturing and testing biologics such as gene therapies, vaccines, and immunotherapies....
This is a definitive, cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL) for support of research on retroviral pathogenesis, treatment, and prevention. The contract has a ceiling value of $6,859,599.39 and a performance period ending on January 29, 2024. The contract does not have a set-aside designation. ABL, a foreign-owned, for-profit manufacturer, specializes in...
This is a prime contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL) on September 20, 2017. The contract has a potential value of $2,044,103.00 and is a Delivery Order for NIAID Preclinical Development Support services. The contract has a completion date of December 31, 2022 and is not set-aside. ABL is a contract research and...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $795,403.00 contract is a delivery order awarded under an existing Indefinite Delivery Vehicle (IDV) for "Advanced Bioscience Laboratories Mucosal Vaccine Technologies". The contract is cost-plus-fixed-fee in type...
This federal contract award, valued at $3,752,675.43, was issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a civilian agency, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The award is for the provision of manufacturing and characterization services for vaccines and other biologics targeting infectious diseases. The contract is a delivery order under ABL's existing Indefinite Delivery Vehicle (IDV) contracts with...